Thrombotic Thrombocytopenic Purpura (TTP)–Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012

On August 13, 2012, a nephrologist reported to the Tennessee Department of Health (TDH) three cases of unexplained thrombotic thrombocytopenic purpura (TTP), a rare but serious blood disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia. The annual incidence is approximately 1 per 100,000 population. Known risk factors for TTP include infection with Shiga toxin-producing Escherichia coli (STEC) and the use of drugs, including platelet aggregation inhibitors, quinine, and cocaine. The three patients were intravenous (IV) drug users who resided in a rural county in northeast Tennessee. To identify other cases of TTP-like illness that might be associated with injection-drug use, TDH conducted a statewide investigation. By the end of October, a total of 15 such cases had been reported; none were fatal. A case-control study was conducted, and investigators determined that the cases of TTP-like illness were associated with dissolving and injecting tablets of Opana ER (Endo Pharmaceuticals), a recently reformulated extended-release form of oxymorphone (an opioid pain reliever) intended for oral administration. Fourteen of the 15 patients reported injecting reformulated Opana ER. Seven of the 15 were treated for sepsis in addition to TTP-like illness. Twelve patients reported chronic hepatitis C or had positive test results for anti-HCV antibody. Health-care providers who prescribe Opana ER and pharmacists who dispense it should inform patients of the risks from the drug when used other than as prescribed. Health-care providers should ask patients with TTP-like illness of unknown etiology about any IV drug abuse. Suspected cases can be reported to public health officials.

[1]  Connie Lim,et al.  Youth risk behavior surveillance - United States, 2011. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[2]  P. V. van Genderen,et al.  Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium , 2012, Malaria Journal.

[3]  Madison,et al.  Malaria surveillance--United States, 2010. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[4]  S. Vesely,et al.  Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. , 2012, Presse medicale.

[5]  Methodologic changes in the Behavioral Risk Factor Surveillance System in 2011 and potential effects on prevalence estimates. , 2012, MMWR. Morbidity and mortality weekly report.

[6]  Vital signs: binge drinking prevalence, frequency, and intensity among adults - United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[7]  Jiaquan Xu,et al.  Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[8]  R. Aungst,et al.  Healthy People 2020 , 2013, American Journal of Kidney Diseases.

[9]  A. Hackshaw,et al.  Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls , 2011, Human reproduction update.

[10]  N. Suttorp,et al.  Intravenous Artesunate for Severe Malaria in Travelers, Europe , 2011, Emerging infectious diseases.

[11]  D. Nelson,et al.  Alcoholic beverage preferences and associated drinking patterns and risk behaviors among high school youth. , 2011, American journal of preventive medicine.

[12]  D. Nelson,et al.  Impact of a new gender-specific definition for binge drinking on prevalence estimates for women. , 2011, American journal of preventive medicine.

[13]  Leonard J. Paulozzi,et al.  Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. , 2011, MMWR. Morbidity and mortality weekly report.

[14]  Kamolrat Silamut,et al.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial , 2010, The Lancet.

[15]  T. Naimi,et al.  US state alcohol sales compared to survey data, 1993-2006. , 2010, Addiction.

[16]  Robert D. Brewer,et al.  Vital signs: binge drinking among high school students and adults --- United States, 2009. , 2010, MMWR. Morbidity and mortality weekly report.

[17]  D. Nelson,et al.  Assessment of Source and Type of Alcohol Consumed by High School Students: Analyses From Four States , 2009, Journal of addiction medicine.

[18]  Kathryn Angus,et al.  Impact of alcohol advertising and media exposure on adolescent alcohol use: a systematic review of longitudinal studies. , 2009, Alcohol and alcoholism.

[19]  D. Nelson,et al.  State alcohol-use estimates among youth and adults, 1993-2005. , 2009, American journal of preventive medicine.

[20]  J. Rankin,et al.  Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. , 2009, JAMA.

[21]  J. Moake,et al.  Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). , 2009, Kidney international. Supplement.

[22]  Lilah M. Besser,et al.  Diabetes mellitus and birth defects. , 2008, American journal of obstetrics and gynecology.

[23]  Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005. , 2008, MMWR. Morbidity and mortality weekly report.

[24]  A. Elixhauser,et al.  Hospitalizations for Birth Defects, 2004 , 2007 .

[25]  D. Sui,et al.  Religious Affiliation and Alcohol Consumption in the United States* , 2006 .

[26]  J. George,et al.  Clinical practice. Thrombotic thrombocytopenic purpura. , 2006, The New England journal of medicine.

[27]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[28]  M. Matsumoto,et al.  Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. , 2005, Journal of hepatology.

[29]  K. W. Harris,et al.  The Guide to Community Preventive Services , 2005 .

[30]  E. V. Abramova,et al.  [Myelotoxicity of high-molecular-weight poly(ethylene oxide)]. , 2004, Eksperimental'naia i klinicheskaia farmakologiia.

[31]  T. Chikritzhs,et al.  Under-reporting of alcohol consumption in household surveys: a comparison of quantity-frequency, graduated-frequency and recent recall. , 2004, Addiction.

[32]  R. Hingson.  Sex differences in adolescent exposure to alcohol advertising in magazines. , 2004, Archives of pediatrics & adolescent medicine.

[33]  U. P. S. T. Force,et al.  Screening and Behavioral Counseling Interventions in Primary Care To Reduce Alcohol Misuse: Recommendation Statement , 2004, Annals of Internal Medicine.

[34]  N. Calonge.  Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. , 2004, American family physician.

[35]  Alcohol-attributable deaths and years of potential life lost--United States, 2001. , 2004, MMWR. Morbidity and mortality weekly report.

[36]  S. Vesely,et al.  The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. , 2004, Seminars in hematology.

[37]  B. C. Gilbert,et al.  Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. , 2003, Pediatrics.

[38]  C. Newbold,et al.  The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. , 2000, The Journal of infectious diseases.

[39]  N. White,et al.  In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. , 1997, Blood.

[40]  R. Thomssen,et al.  Prolonged haemolytic anaemia in malaria and autoantibodies against triosephosphate isomerase , 1993, The Lancet.

[41]  J. Mulinare,et al.  Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[42]  C. Lieber,et al.  High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. , 1990, The New England journal of medicine.

[43]  D. Weatherall,et al.  The Anaemia of P. falciparum Malaria , 1980, British journal of haematology.

[44]  A. W. Woodruff,et al.  CAUSE OF ANÆMIA IN MALARIA , 1979, The Lancet.

[45]  A. W. Woodruff,et al.  Cause of anaemia in malaria. , 1979, Lancet.